SCHEMBL7225435

SCHEMBL7225435

Cc1nc(-c2ccccn2)sc1C(=O)N[C@H]1CN2CCC1CC2

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 8/20 0.64
KDM4E B2RXH2 3/20 0.60
GAA P10253 1/20 0.60
ALDH1A1 P00352 2/20 0.54
KMT2A Q03164 1/20 0.54
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
HTR3A P46098 3/20 0.49
HTR3E A5X5Y0 2/20 0.49
HTR3B O95264 2/20 0.49
HTR3D Q70Z44 2/20 0.49
HTR3C Q8WXA8 2/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7122325 0.99 CHRNA7 (0.63) CHRNA7KDM4EGAAALDH1A1KMT2A
SCHEMBL7225459 0.85 CHRNA7 (0.64) CHRNA7GAAALDH1A1MAPTHPGD
Hydrochloric Acid SCHEMBL7122469 0.85 CHRNA7 (0.62) CHRNA7GAAALDH1A1MAPTHPGD
SCHEMBL7530755 0.82 CHRNA7 (0.54) CHRNA7POLBMAPTHTR3AHTR3E
SCHEMBL7122337 0.82 CHRNA7 (0.54) CHRNA7POLBMAPTHTR3AHTR3E
Hydrochloric Acid SCHEMBL7123494 0.82 CHRNA7 (0.53) CHRNA7POLBMAPTHTR3AHTR3E
SCHEMBL7125439 0.81 KDM4E (0.59) CHRNA7KDM4EGAAALDH1A1KMT2A
SCHEMBL7124992 0.81 CHRNA7 (0.74) CHRNA7ALDH1A1HTR3AHTR3EHTR3B
SCHEMBL7224488 0.80 SMN1; SMN2 (0.59) CHRNA7KDM4EGAAALDH1A1KMT2A
SCHEMBL5072917 0.78 CHRNA7 (0.64) CHRNA7HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599916-B2 Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated, Alzheimer's disease, pre-senile dementia (mild cognitive impairment), or senile dementia. PHARMACIA & UPJOHN COMPANY 2003-07-29 US claimed
US-6500840-B2 CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2002-12-31 US claimed
US-6492385-B2 CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2002-12-10 US claimed
US-20020091135-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY 2002-07-11 US claimed
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PHARMACIA & UPJOHN COMPANY 2002-04-11 US claimed
US-20020042429-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PHARMACIA & UPJOHN COMPANY 2002-04-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease NQO2, GBA1, UGT1A1 CHRNA7 304/4885KDM4E 3718/4885GAA 5/4885
US-20020042429-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PARK7, CYP3A7, UGT2B7 CHRNA7 28/4885KDM4E 4040/4885GAA 24/4885
US-20020091135-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease NQO2, GBA1, UGT1A1 CHRNA7 304/4885KDM4E 3718/4885GAA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.